Key Points
Bristol-Myers Squibb Company (BMY) advanced sharply in today’s session, closing at $51.00 versus a prior close of $48.25, gaining 5.70% and adding $2.75 on the day. The move put shares firmly on the front foot as buyers stepped in early and sustained interest into the close, reflecting renewed confidence in the company’s outlook and a constructive shift in sentiment.
Trading activity was robust: Volume reached 15,852,572 shares, exceeding the 90-day average of 14,609,799, a sign that the rally drew in incremental participation beyond typical daily flows. Even after today’s pop, BMY remains 19% below its 52-week high of $63.33, leaving room for recovery if positive momentum persists. The combination of a strong single-day gain, heavier-than-average turnover, and improving tone suggests bulls are pressing an advantage after a period of underperformance.
The move also comes with a supportive backdrop for income-focused investors, with a 5.14% dividend yield providing carry while the stock rebuilds a base. From a large-cap vantage point, Bristol-Myers Squibb’s $98.23 billion market value and established portfolio give buyers confidence that a single-day move can evolve into a steadier trend when accompanied by constructive headlines and execution. Overall, the day’s action marks a decisive, upbeat inflection that points to improving momentum and broadening investor interest in BMY.
Why Bristol-Myers Squibb Company Price is Moving Higher
BMY’s strong finish at $51.00, up 5.70% on elevated volume (15,852,572 vs. a 90-day average of 14,609,799), reflects a clear catalyst-driven session. Shares rallied after the company confirmed it will continue enrollment in the ADEPT-2 Phase 3 trial for Cobenfy in psychosis associated with Alzheimer’s disease, following recommendations from the independent Data Monitoring Committee and the FDA. While data from certain sites will be excluded due to irregularities, management will add patients and now expects full results by year-end 2026. Importantly, analyst commentary from JPMorgan and William Blair framed the decision as a “non-failure” outcome, helping reset expectations and reignite interest after a challenging year.
This pipeline update landed alongside resilient fundamentals. Bristol-Myers Squibb recently delivered a solid Q3 2025 print with EPS of $1.63 versus $1.52 expected and revenue of $12.22 billion versus $11.75 billion forecast, reflecting 2.8% year-over-year growth and supporting full-year EPS guidance of $6.40–$6.60. With a market cap of $98.23 billion, EPS (TTM) of $2.96, and shares still 19% below the 52-week high of $63.33, investors viewed the setup as an attractive way to gain exposure to a diversified portfolio plus a late-stage asset with meaningful potential in a large unmet-need indication.
Put together, the positive trial-enrollment decision, supportive regulator and DMC signals, and better-than-expected quarterly execution created a favorable backdrop for risk-taking. The above-average trading volume underscored conviction, and the valuation context helped buyers lean into the move, translating news and fundamentals into broad-based, bullish momentum for BMY.
What is the Bristol-Myers Squibb Company Rating - Should I Buy?
Weiss Ratings assigns BMY a C rating. Current recommendation is Hold.
The rating is built on six indices: the Good Growth Index (measures revenue and earnings expansion) reflects gradual improvement consistent with 2.77% revenue growth; the Good Efficiency Index (measures operational effectiveness and profit margins) aligns with a 12.57% profit margin and a 33.77% ROE; and the Excellent Solvency Index (measures financial health and debt management) indicates strong balance-sheet capacity to fund R&D, dividends, and strategic investments. Offsetting these positives, the Weak Total Return Index (measures stock price appreciation plus dividends) and the Weak Volatility Index (measures price stability and risk) signal choppier trading and uneven risk-adjusted performance. The Good Dividend Index (measures dividend payments and yield) is supported by a 5.14% yield, while a 16.33 P/E ratio suggests a reasonable valuation relative to earnings power.
Relative to peers, sector constituents LLY (C), JNJ (B), and ABBV (C) show a mixed competitive field. JNJ’s B rating highlights stronger risk-adjusted consistency, while BMY compares favorably on income with its higher yield. Against LLY and ABBV, BMY’s index mix is more balanced on solvency and dividends but lags on total return momentum.
Net-net, the C (Hold) reflects a risk/reward that is about average: sound solvency, healthy efficiency, and an attractive dividend are meaningful strengths, yet weaker total return history and volatility constrain the overall profile. For investors, the rating signals a constructive but measured stance while the company works to convert pipeline catalysts into sustained performance.
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company is a global biopharmaceutical leader in the Health Care sector, operating within the Pharmaceuticals, Biotechnology and Life Sciences industry. The company discovers, develops, and delivers innovative medicines that address serious diseases where high unmet needs persist across oncology, hematology, immunology, cardiovascular, and neuroscience.
Its commercial portfolio includes widely used therapies such as Eliquis (apixaban) for thromboembolic disorders; Opdivo (nivolumab) and Yervoy (ipilimumab) in immuno-oncology; Orencia (abatacept) for immune-mediated conditions; and Revlimid (lenalidomide) and Pomalyst (pomalidomide) in hematologic malignancies. Bristol-Myers Squibb has expanded into cell therapy with Breyanzi (lisocabtagene maraleucel) and Abecma (idecabtagene vicleucel, in collaboration with 2seventy bio), reinforcing its position in next-generation oncology treatments. Additional assets such as Zeposia (ozanimod) in immunology and Camzyos (mavacamten) in cardiovascular disease broaden the company’s reach across key therapeutic categories.
The firm’s competitive advantages include deep scientific expertise, global scale in clinical development and manufacturing, and a diversified pipeline spanning small molecules, biologics, and cell therapies. A disciplined approach to research and development, combined with strategic partnerships and selective acquisitions, supports a steady cadence of innovation. With an established commercial infrastructure and extensive regulatory experience, Bristol-Myers Squibb is positioned to advance late-stage programs and deliver complex therapies worldwide, aiming to improve patient outcomes across multiple high-need diseases while maintaining a balanced portfolio of mature brands and emerging growth drivers.
Investor Outlook
Momentum in BMY has improved alongside constructive pipeline updates and solid execution, and the C (Hold) rating reflects a balanced, risk-aware stance while further catalysts develop. Income support from a robust dividend and a disciplined balance sheet add resilience as the company works to convert late-stage assets into durable growth.
See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.